DNA修復薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、用途別、流通チャネル別、地域別、競合市場別、2020-2030年

DNA修復薬の世界市場規模は2024年に78億5,000万米ドルに達し、2030年までのCAGRは12.85%で、予測期間中に力強い成長が予測されています。

世界のDNA修復薬市場は、医薬品・ヘルスケア産業の中でもダイナミックで急速に発展している分野です。DNA修復薬は、細胞のDNAの異常を標的とし、それを修正するように設計された薬剤の特殊なカテゴリーです。これらの医薬品は、DNA損傷や突然変異が疾患進行の主要因となる遺伝性疾患や様々ながんの治療において重要な役割を果たしています。この市場概要では、世界の情勢を形成している主要な要因、動向、課題、機会に関する洞察を提供します。

市場促進要因

がん罹患率の増加

主な市場課題

DNA修復機構の複雑さ

主要市場動向

精密医療と個別化治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のDNA修復薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤の種類別（アルキル化剤、PARP阻害剤、トポイソメラーゼ阻害剤、その他）
  • 用途別（神経変性疾患、腫瘍、心血管疾患、脳卒中）
  • 流通チャネル別（小売薬局、病院薬局、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のDNA修復薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のDNA修復薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のDNA修復薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のDNA修復薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのDNA修復薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のDNA修復薬市場：SWOT分析

第14章 競合情勢

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Abbvie Inc.
• Pfizer Inc.
• Astrazeneca plc
• Sanofi S.A.
• Bayer AG
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Novartis AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global DNA Repair Drugs Market was valued at USD 7.85 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 12.85% through 2030. The Global DNA Repair Drugs Market is a dynamic and rapidly evolving segment of the pharmaceutical and healthcare industry. DNA repair drugs are a specialized category of medications designed to target and correct abnormalities in the DNA of cells. These drugs play a critical role in the treatment of genetic diseases and various forms of cancer, where DNA damage and mutations are key drivers of disease progression. This market overview provides insights into the key factors, trends, challenges, and opportunities shaping the landscape of the Global DNA Repair Drugs Market.

Key Market Drivers

Increasing Cancer Incidence

The global population is aging, and this demographic shift has a significant impact on cancer incidence. Cancer can occur at any age; however, its prevalence increases significantly with aging. In 2022, approximately 53% of diagnosed cancer cases were in individuals aged 65 and above, highlighting the strong correlation between aging populations and rising cancer incidence. With increasing age, individuals are more susceptible to genetic mutations that can lead to cancer. As the elderly population grows, so does the prevalence of cancer, creating a substantial demand for innovative treatments like DNA repair drugs. Modern lifestyles often involve exposure to numerous cancer risk factors, including poor dietary habits, sedentary lifestyles, and increased consumption of tobacco and alcohol. Research indicates that 90-95% of cancer cases can be attributed to environmental and lifestyle factors, emphasizing a significant preventable risk component. These lifestyle choices contribute to the rise in cancer cases. DNA repair drugs are seen as potential solutions to address the genetic damage caused by such risk factors.

Key Market Challenges

Complexity of DNA Repair Mechanisms

One of the primary challenges in the development of DNA repair drugs is the intricate nature of DNA repair mechanisms. DNA repair is a highly regulated and multifaceted process involving various enzymes, pathways, and checkpoints. Different types of DNA damage require specific repair mechanisms. Designing drugs that can effectively target and modulate these complex processes while minimizing off-target effects is a formidable task. Additionally, DNA repair mechanisms vary between individuals, making it challenging to create a one-size-fits-all solution. Personalized medicine approaches require tailoring treatments to an individual's genetic profile, further complicating drug development and clinical trials.

Key Market Trends

Precision Medicine and Personalized Treatment

One of the most significant trends in the DNA Repair Drugs Market is the shift towards precision medicine. Advances in genomics and molecular diagnostics have enabled healthcare providers to tailor treatment plans to an individual's genetic profile. This trend recognizes that each patient's genetic makeup is unique, influencing their response to DNA repair drugs and other therapies. By identifying specific genetic mutations and DNA repair deficiencies in patients, healthcare professionals can select the most appropriate DNA repair drugs or combination therapies. This approach maximizes treatment efficacy while minimizing side effects, representing a paradigm shift in healthcare towards personalized, patient-centric treatments.

Key Market Players

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Abbvie Inc.
• Pfizer Inc.
• Astrazeneca plc
• Sanofi S.A.
• Bayer AG
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Novartis AG

Report Scope:

In this report, the Global DNA Repair Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Repair Drugs Market, By Drug Type:

• Alkylating Agents
• PARP Inhibitors
• Topoisomerase Inhibitors
• Other

DNA Repair Drugs Market, By Application:

• Neurodegenerative Diseases
• Oncological
• Cardiovascular Diseases
• Stroke

DNA Repair Drugs Market, By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Others

DNA Repair Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Repair Drugs Market.

Available Customizations:

Global DNA Repair Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Repair Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Alkylating Agents, PARP Inhibitors, Topoisomerase Inhibitors, Other)
  • 5.2.2. By Application (Neurodegenerative Diseases, Oncological, Cardiovascular Diseases, Stroke)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America DNA Repair Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Repair Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada DNA Repair Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico DNA Repair Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe DNA Repair Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Repair Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom DNA Repair Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy DNA Repair Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France DNA Repair Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain DNA Repair Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific DNA Repair Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China DNA Repair Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India DNA Repair Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan DNA Repair Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea DNA Repair Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia DNA Repair Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America DNA Repair Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil DNA Repair Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina DNA Repair Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia DNA Repair Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa DNA Repair Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa DNA Repair Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia DNA Repair Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE DNA Repair Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global DNA Repair Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. GlaxoSmithKline plc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Abbvie Inc.
• 14.4. Pfizer Inc.
• 14.5. Astrazeneca plc
• 14.6. Sanofi S.A.
• 14.7. Bayer AG
• 14.8. Gilead Sciences Inc.
• 14.9. Merck & Co. Inc.
• 14.10.Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer